CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on June 21, 2024
FIBROBIOLOGICS, INC.
455 E. Medical Center Blvd.
Suite 300
Houston, Texas 77598
June 21, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Doris Stacey Gama |
| RE: | FibroBiologics, Inc. (the “Company”) | |
| Registration Statement on Form S-1 | ||
| File No. 333-280303 |
Dear Mrs. Gama:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-280303) be accelerated by the Securities and Exchange Commission to 5:00 p.m. Washington D.C. time on June 25, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.
We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| FibroBiologics, Inc. | ||
| By: | /s/ Mark Andersen | |
| Name: | Mark Andersen | |
| Title: | Chief Financial Officer | |